



M47

Principles and Procedures for Blood Cultures

This guideline includes recommendations for collecting, transporting, and processing specimens for blood culture, as well as procedures for recovering pathogens from the blood of patients with suspected bacteremia or fungemia.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the *CLSI Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

Principles and Procedures for Blood Cultures

Michael L. Wilson, MD
Thomas J. Kirn, Jr., MD, PhD
Stella Antonara, PhD, D(ABMM)
Jeffrey Brocius, MS, MT(ASCP)
Karen C. Carroll, MD
Robin Chamberland, PhD, D(ABMM)
Raymund Dantes, MD, MPH
Jennifer Dien Bard, PhD, D(ABMM), F(CCM)
Leonard K. Dunikoski, Jr., PhD, DABCC
Mukesh Gandhi, CMLTO
Christine C. Ginocchio, PhD, MT(ASCP)
Nancy Glasgow-Roberts, PBT(ASCP)

Mark D. Gonzalez, PhD, D(ABMM)
Camille Hamula, PhD, FCCM, D(ABMM)
Romney M. Humphries, PhD, D(ABMM)
Robert C. Jerris, PhD, D(ABMM)
Amy L. Leber, PhD, D(ABMM), SM(ASCP)MB
Margaret Ordóñez Smith de Danies, PhD
David R. Peaper, MD, PhD, D(ABMM)
L. Barth Reller, MD
Barbara Schenk, MLS(ASCP)^{CM}, MPA
Audrey N. Schuetz, MD, MPH, D(ABMM)
Melvin P. Weinstein, MD
Melanie Yarbrough, PhD

Abstract

Clinical and Laboratory Standards Institute guideline M47—*Principles and Procedures for Blood Cultures* provides recommendations for laboratory detection of bacteremia and fungemia using blood cultures. This guideline also includes recommendations for collecting, transporting, and processing specimens for blood culture and for interpreting and reporting results. Critical factors in the recovery of pathogens from blood specimens and related topics are also covered.

Clinical and Laboratory Standards Institute (CLSI). *Principles and Procedures for Blood Cultures*. 2nd ed. CLSI guideline M47 (ISBN 978-1-68440-148-2 [Print]; ISBN 978-1-68440-149-9 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2022.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100 **F:** +1.610.688.0700 **E:** customerservice@clsi.org **W:** www.clsi.org

Copyright ©2022 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Principles and Procedures for Blood Cultures*. 2nd ed. CLSI guideline M47. Clinical and Laboratory Standards Institute; 2022.

Previous Edition:

May 2007

M47-Ed2

ISBN 978-1-558-68440-2 (Print)

ISBN 978-1-558-68440-9 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 42, Number 10

Committee Membership

Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: <https://clsi.org/standards-development/consensus-council>

Document Development Committee on Blood Cultures

Michael L. Wilson, MD
Chairholder
Denver Health & Hospital Authority
USA

Raymund Dantes, MD, MPH
 Emory University School of Medicine
 USA

Robert C. Jerris, PhD, D(ABMM),
 Children's Healthcare of Atlanta
 USA

Thomas J. Kirn, Jr., MD, PhD
Vice-Chairholder
Rutgers Robert Wood Johnson
Medical School
USA

Jennifer Dien Bard, PhD, D(ABMM),
 F(CCM)
 Children's Hospital Los Angeles,
 University of Southern California
 USA

L. Barth Reller, MD
 Duke University School of Medicine
 USA

Jeffrey Brocius, MS, MT(ASCP)
 FDA Center for Devices and
 Radiological Health
 USA

Christine C. Ginocchio, PhD, MT(ASCP),
 bioMérieux, Inc.
 USA

Audrey N. Schuetz, MD, MPH,
 D(ABMM)
 Mayo Clinic
 USA

Karen C. Carroll, MD
 Johns Hopkins University School of
 Medicine
 USA

Romney M. Humphries, PhD,
 D(ABMM)
 Vanderbilt University Medical Center
 USA

Melvin P. Weinstein, MD
 Robert Wood Johnson University
 Hospital
 USA

Expert Panel on Microbiology

Expert Panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert Panel members are listed by area of expertise on the CLSI website: <https://clsi.org/standards-development/expert-panels>

Staff

Clinical and Laboratory Standards
 Institute
 USA

Laura Martin
Editorial Manager

Kristy L. Leirer, MS
Editor

Emily J. Gomez, MS, MLS(ASCP)^{CM}MB^{CM}
Project Manager

Catherine E.M. Jenkins, ELS
Editor

Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Blood Cultures gratefully acknowledge the following volunteers for their important contributions to the revision of this guideline:

Stella Antonara, PhD, D(ABMM)
Ohio Health
USA

Mark D. Gonzalez, PhD, D(ABMM)
Children's Healthcare of Atlanta
USA

David R. Peaper, MD, PhD, D(ABMM)
Yale University/Department of
Veterans Affairs
USA

Robin Chamberland, PhD, D(ABMM)
Saint Louis University School of
Medicine
USA

Camille Hamula, PhD, FCCM,
D(ABMM)
Saskatchewan Health Authority/
University of Saskatchewan College of
Medicine
Canada

Barbara Schenk, MLS(ASCP)^{CM}, MBA
BD Diagnostic Systems
USA

Leonard K. Dunikoski, Jr., PhD, DABCC
Becton Dickinson Life Sciences
USA

Amy L. Leber, PhD, D(ABMM),
SM(ASCP)MB
Nationwide Children's Hospital
USA

Melanie Yarbrough, PhD
Washington University School of
Medicine
USA

Mukesh Gandhi, CMLTO
Dynacare Health Solutions
Canada

Nancy Glasgow-Roberts, PBT(ASCP)
USA

Margaret Ordóñez Smith de Danies,
PhD
Microbiology Institute of Colombia
Colombia

Contents

Abstract	i
Committee Membership	iii
Foreword	vii
Chapter 1: Introduction	1
1.1 Scope	1
1.2 Background	2
1.3 Standard Precautions	2
1.4 Terminology	3
Chapter 2: Blood Culture Path of Workflow	7
Chapter 3: Preexamination Activities	9
3.1 Patient Assessment	10
3.2 Examination Requisition	11
3.3 Precollection Requirements	12
3.4 Specimen Collection	15
3.5 Specimen Labeling	20
3.6 Specimen Transportation	20
3.7 Specimen Receipt and Processing	21
3.8 Specimen Rejection Criteria	22
Chapter 4: Examination Activities	23
4.1 Medium Types, Indications, and Formulations	24
4.2 Additives	24
4.3 Incubation Conditions	25
4.4 Examination Process	26
Chapter 5: Blood Culture Methods	29
5.1 Standard Blood Culture Methods	30
5.2 Conventional Blood Culture Methods	32
5.3 Continuous-Monitoring Blood Culture Systems	34
5.4 Rapid Identification of Blood Culture Isolates	35
5.5 Direct Antimicrobial Susceptibility Testing	37
5.6 Direct Detection of Bloodstream Pathogens	40

Contents (Continued)

Chapter 6: Postexamination Activities	43
6.1 Monitoring of Contamination Rates	44
6.2 Results Reporting	45
6.3 Monitoring of Catheter-Related Bloodstream Infections	48
6.4 Blood Culture Isolate Storage	48
Chapter 7: Recovery of Rare and Fastidious Pathogens	51
7.1 <i>Abiotrophia</i> and <i>Granulicatella</i>	52
7.2 <i>Bartonella</i>	53
7.3 <i>Brucella</i>	53
7.4 <i>Campylobacter</i>	53
7.5 <i>Francisella</i> and HACEK Group	54
7.6 <i>Helicobacter</i>	54
7.7 <i>Legionella</i>	54
7.8 <i>Leptospira</i>	55
7.9 <i>Mycoplasma</i>	55
Chapter 8: Special Considerations	57
8.1 Patients Receiving Antimicrobial Therapy	58
8.2 Infective Endocarditis	58
8.3 Follow-up and Surveillance Blood Cultures	60
8.4 Mycobacterial Blood Cultures	60
8.5 Fungal Blood Cultures	62
Chapter 9: Quality System Essentials	65
9.1 Facilities and Safety Management	66
9.2 Supplier and Inventory Management	66
9.3 Process Management	67
9.4 Documents and Records Management	68
9.5 Information Management	69
9.6 Assessments	69
Chapter 10: Conclusion	71
Chapter 11: Supplemental Information	73
References	74
Additional Resource	97
The Quality Management System Approach	98

Foreword

Because the morbidity and mortality rates attributable to sepsis are high, the prompt and accurate detection of bacteremia and fungemia is important to improving patient care. The laboratory test used to detect the presence of bacteria (bacteremia), mycobacteria (mycobacteremia), or fungi (fungemia) in the blood is the blood culture.¹ In the past 40 years, several studies²⁻¹⁰ have been conducted to:

- Define the clinical significance of blood cultures.
- Identify the indications for blood cultures.
- Define the critical factors in the recovery of pathogens from blood.
- Identify the best medium formulations and establish best practices for facilities that perform blood cultures.
- Develop interpretive criteria to evaluate the significance of positive blood cultures.
- Evaluate and compare commercial blood culture systems.

The selection and use of optimal blood specimen collection, transport, and processing procedures is critical to ensuring accurate and timely results reporting. Since this guideline was first published in 2007, research and development in the preexamination, examination, and postexamination phases of blood cultures have advanced. In addition, changes in blood culture technology have resulted in new methods for recovering and identifying pathogens from blood cultures and for detecting antimicrobial resistance markers. Because the field continues to evolve, this guideline incorporates recommended practices for collecting, transporting, processing, testing, and storing blood culture specimens. This guideline is also intended to help control health care costs, because the costs attributable to the recovery and identification of pathogens from blood cultures are high.

Overview of Changes

This guideline replaces the previous edition of the approved guideline, M47-A, published in 2007. Several changes were made in this edition, including:

- Describing critical factors in recovering pathogens from blood specimens and providing guidance on selecting the best medium formulations, developing and applying breakpoints, and reporting results
- Describing existing technologies capable of identifying the etiology of bloodstream infections (BSIs) and the benefits of using these technologies (including culture-independent methods)
- Adding subchapters on special topics, including pediatric blood cultures, catheter-related BSIs, infective endocarditis, patients receiving antimicrobial therapy, and rare and fastidious pathogens
- Including example quality assurance indicators for preexamination, examination, and postexamination activities
- Removing descriptions of paper-based test ordering and results reporting, because the widespread use of electronic medical record systems has changed the way blood cultures are ordered and results are reported

NOTE: The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

KEY WORDS

Bacteremia

Bloodstream infection

Mycobacteria

Bacteria

Fungemia

Sepsis

Blood culture

Fungi

Currently in preview, click buy full version

Chapter ①

Introduction

Principles and Procedures for Blood Cultures

1 Introduction

1.1 Scope

This guideline is intended to provide recommendations to clinical microbiologists, other laboratorians (eg, pathologists, supervisors and/or managers, phlebotomists), and health care providers (HCPs) for recovering pathogens from the blood of patients with suspected bacteremia, mycobacteremia, or fungemia. It is also intended for administrators who develop institutional best practices. Specific recommendations for collecting, transporting, and processing blood culture specimens are also included.

This guideline discusses the clinical significance of blood cultures, critical factors in recovering pathogens from blood specimens, selection of medium formulations and other laboratory practices, and development of interpretive criteria. It also discusses existing blood culture technologies and the relative benefits of these technologies. Special topics, including pediatric blood cultures; catheter-related bloodstream infections (CRBSIs); infective endocarditis; diagnostic testing for patients who are receiving antimicrobial therapy; rare and fastidious pathogens; and rapid diagnostic techniques, including culture-independent methods, are also covered.

This guideline does not include procedures for pathogen ID and antimicrobial susceptibility testing (AST). For guidance on bacterial AST, refer to CLSI documents M02,¹¹ M07,¹² M11,¹³ M45,¹⁴ and M100.¹⁵ For guidance on fungal AST, refer to CLSI documents M27,¹⁶ M38,¹⁷ M44,¹⁸ M51,¹⁹ M60,²⁰ and M61.²¹

1.2 Background

The presence of living microorganisms in a patient's bloodstream has diagnostic and prognostic importance.² Therefore, when performed properly and in the appropriate clinical setting, blood cultures provide substantial value. Positive blood culture results either establish or confirm an infectious etiology of a patient's illness. Moreover, they also provide the etiological agent for AST, which, in turn, optimizes antimicrobial therapy.

From a prognostic standpoint, a blood culture that grows a clinically important pathogen indicates failure of the patient's immune system to contain the infection at its primary location or failure of the patient's HCP to remove, drain, or otherwise eradicate the cause of an infectious disease. The type of pathogen recovered from the patient's blood also provides important prognostic information.²

1.3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to "standard precautions." Standard precautions are guidelines that combine the major features of "universal precautions and body substance isolation" practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory.²² For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.²³